Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceBrain & cognition

L-Serine

L-serine is a non-essential amino acid with a genuine and growing clinical research program — but it is in rare neurological disease (serine biosynthesis defects, HSAN1, ALS trials), not in healthy people. As a general nootropic or sleep aid it has essentially no supporting human evidence.

What the science says

  • Established treatment only for inborn serine biosynthesis disorders Strong evidence

    In 3-phosphoglycerate dehydrogenase deficiency and related serine synthesis defects, high-dose oral L-serine (typically 200-700 mg/kg/day, sometimes with glycine) normalizes CSF serine, reduces or abolishes seizures, and improves myelination — this is the one setting where L-serine is unequivocally effective. These are ultra-rare genetic conditions diagnosed by CSF amino acid analysis, not something a supplement buyer self-treats.

  • Reduces neurotoxic deoxysphingolipids in HSAN1, with modest clinical signal Moderate evidence

    A randomized placebo-controlled trial in hereditary sensory and autonomic neuropathy type 1 gave 400 mg/kg/day L-serine for one year; it lowered plasma neurotoxic 1-deoxysphingolipids and showed a small improvement in the CMT Neuropathy Score compared with placebo, which continued worsening. The effect was modest and the trial was small (18 completers), but the mechanism-to-outcome link is unusually clean.

  • ALS and cognition data are preliminary, not practice-changing Limited evidence

    A phase I dose-escalation trial in 20 ALS patients found L-serine up to 30 g/day was tolerated and suggested a possible slowing of ALSFRS-R decline in a post-hoc comparison to a historical control cohort — a design that cannot demonstrate efficacy. Claims that L-serine improves sleep, memory or mood in healthy adults are extrapolated from D-serine's NMDA co-agonist role and from animal work; no placebo-controlled trial supports them.

Dosage & safety

Studied doseClinical doses are far above supplement labels: 400 mg/kg/day in HSAN1, up to 30 g/day in the ALS phase I, 200-700 mg/kg/day in serine biosynthesis defects. Tolerance testing in healthy adults has covered graded doses over four weeks without adverse effect. Consumer products typically supply 500-2,000 mg/day, a dose with no efficacy data behind it for any consumer claim.
SafetyWell tolerated in trials, with GI upset (nausea, loose stools) the main dose-limiting complaint at multi-gram doses. Note that L-serine is distinct from D-serine — D-serine at high dose has been associated with nephrotoxicity in animals and requires monitoring in human trials; do not substitute one for the other. High-dose use in kidney disease is unstudied and should be medically supervised. Interactions are not well characterized. Serious neurological uses (ALS, HSAN1, seizure disorders) belong in a neurologist's hands, not in self-treatment. Not banned in sport.

Scientific references

Where to buy

Vitamatic, L-Serine Powder, 8.8 oz (250 g)

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Brain & cognition